A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer's Disease
Phase of Trial: Phase II
Latest Information Update: 07 Sep 2017
At a glance
- Drugs C2N 8E12 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors AbbVie
- 31 Aug 2017 Planned End Date changed from 3 Jun 2021 to 7 Apr 2021.
- 20 Jul 2017 Study design presented at the Alzheimer's Association International Conference 2017.
- 08 May 2017 Planned End Date changed from 7 Apr 2021 to 3 Jun 2021.